Background: Aromatase inhibitors are the preferred adjuvant endocrine therapy for the majority of postmenopausal women with hormone-responsive early breast cancer. Although generally more effective than tamoxifen, aromatase inhibitor therapy is associated with increased bone loss and fracture risk.
introduction
Aromatase inhibitor treatment is an accepted standard of care for postmenopausal women with hormone-receptor-positive (HR + ) breast cancer [1, 2] and may be used upfront or as sequential treatment with tamoxifen [3] [4] [5] . Letrozole is a nonsteroidal aromatase inhibitor, and one of three agents approved for use in postmenopausal women with HR + breast cancer.
Aromatase inhibitors block oestrogen production in peripheral tissues, thereby decreasing circulating oestrogen to undetectable levels in postmenopausal women [6] . Although oestrogen suppression is central to treating hormone-responsive early breast cancer, oestrogen is also essential for maintaining bone mineral density (BMD). Reduced oestrogen levels, whether caused by natural or iatrogenic menopause, lead to increased bone turnover and a decline in BMD [7, 8] . During aromatase inhibitor therapy, further suppression of postmenopausal oestrogen levels results in an acceleration in bone turnover, bone loss, and increased rates of bone fractures [9, 10] . Nitrogen-containing bisphosphonates such as zoledronic acid (zoledronate) inhibit osteoclast-mediated bone resorption [11, 12] and help maintain BMD in postmenopausal women [13] . Clinical studies have shown that zoledronate preserves BMD in patients receiving adjuvant chemotherapy or aromatase inhibitors for early breast cancer [6, [14] [15] [16] . Moreover, preclinical and translational data [17, 18] , as well as clinical studies [19] [20] [21] , suggest that bisphosphonates may provide anticancer benefits in addition to their established bone-protective activities. In particular, there are data suggesting anticancer activity with zoledronate in women receiving adjuvant endocrine therapy for early breast cancer, including a previous report of the ZO-FAST study [20] and the Austrian Breast and Colorectal Cancer Study Group trial 12 [21] . These findings are supported by the results of the AZURE trial, which evaluated the potential effects of zoledronate therapy on disease outcomes in women with stage II/III breast cancer (not limited by menopausal status, hormone-receptor status of primary tumours, baseline BMD, or adjuvant treatment) [19] . Although zoledronate treatment did not improve disease-free survival (DFS) in the overall patient population, substantial improvements in both DFS and overall survival (OS) were seen in pre-planned subset analyses of women who had been postmenopausal for at least 5 years at study entry [19] .
We previously reported early improvements in DFS in addition to increased BMD after 36 months' follow-up in the ZO-FAST trial [20] . Here, we report that the final study results from the ZO-FAST trial after 60-month follow-up, together with subgroup analyses designed to provide additional insight into the characteristics of patients with early stage BC who are most likely to derive adjuvant benefit from zoledronate. methods study design and patients ZO-FAST is an open-label, multicentre, randomised, phase III study. Enrolment criteria, study design, and ethics review for ZO-FAST were previously described [6] . Briefly, ZO-FAST enrolled postmenopausal women with oestrogen-and/or progesterone-receptor-positive [ER + /PgR + ]; stage I, II, or IIIA early breast cancer; baseline Eastern Cooperative Oncology Group (ECOG) score ≤2; baseline lumbar spine and total hip T-scores ≥ −2; surgical resection completed; and chemotherapy and/or radiation therapy completed during the previous 12 weeks without evidence of residual disease. Exclusion criteria included clinical or radiological evidence of distant metastases; pre-existing lumbar spine or hip fractures or a history of low-intensity fractures; renal dysfunction; other malignancies; or diseases known to affect bone density. Prior treatments with letrozole or other adjuvant endocrine therapy, hormone replacement, intravenous bisphosphonates, or prolonged treatments with drugs that affect the skeleton were also not allowed.
treatment
All patients received oral daily letrozole 2.5 mg for 5 years and were randomised to receive either immediate or delayed treatment with zoledronate 4 mg, administered intravenously once every 6 months. In the immediate arm, patients initiated zoledronate within 1 month of randomisation and continued for 5 years. In the delayed arm, patients received zoledronate after initiating letrozole if their T-score fell below −2 or if they had a fracture (non-traumatic clinical fracture, or asymptomatic fracture detected at the 36-month assessment). Patients in both treatment groups also received daily oral calcium and vitamin D supplements.
Yearly BMD assessments were made using standardised, cross-calibrated dual-energy X-ray absorptiometry equipment, and all scans underwent central review.
efficacy and safety endpoints
The primary end point was the percentage change in lumbar spine (L1-L4) BMD at 12 months in the immediate-and delayed-zoledronate treatment arms. Secondary end points included percentage changes in lumbar spine and total hip BMD at years 2, 3, 4, and 5; incidence of fractures over 3 years, time to disease recurrence (i.e. DFS), OS, and safety. Adverse events (AEs) and laboratory evaluations were safety end points. Preplanned analyses by menopausal status (recently or established) were performed. 'Recently postmenopausal' referred to women who became menopausal following the diagnosis of breast cancer but before randomisation (e.g. due to adjuvant chemotherapy, oophorectomy, or ovarian suppression therapy).
statistical analyses
Stratification factors before randomisation included adjuvant chemotherapy, baseline T-score, and menopausal status at diagnosis. All analyses were performed on an ITT basis unless stated as otherwise.
DFS was defined as time to disease recurrence (invasive local, regional, or distant metastasis) or death from any cause. Second malignancies were not included in the DFS definition. ITT analyses at 12, 36, 48, and 60 months were prospectively planned. To control for potentially confounding effects from post-baseline zoledronate initiation in the delayed arm, DFS was also evaluated in analyses censoring delayed-arm patients on the date delayed intervention with zoledronate started. Furthermore, an exploratory unplanned Cox regression analysis evaluated the effects on DFS of initiating zoledronate in the delayed-zoledronate group.
The effects of immediate versus delayed zoledronate on BMD, DFS, and OS were also assessed in exploratory Cox regression models including baseline menopausal status per prospective criteria, menopausal status according to the criteria used in the AZURE trial [19] , and age categories (age <50; ≥50 but <60; ≥60 but <70; ≥70 years old at study entry). All statistical analyses were conducted under the supervision of the Novartis trial statistician (NM).
AEs were assessed by the treatment arm. Patients who received their first zoledronate infusion within 4 weeks of randomisation were regarded as the immediate treatment group. Patients receiving delayed start (>4 weeks from randomisation) zoledronate were regarded as the delayed intervention (control) group.
results patient disposition
A total of 1065 patients from 132 centres across 28 countries were randomised to one of two treatment arms. Patient demographics and disposition were similar between the treatment groups ( Table 1 , supplementary Figure S1 , available at Annals of Oncology online), as previously reported [6, 20] . Final analyses at study completion at 60 months are presented.
treatments
Patients in both groups were treated with letrozole for a median of ∼60 months (range 0-67.8 months). A median of 11 infusions of zoledronate were administered to 532 patients in the immediate-zoledronate group. In the delayed-zoledronate group, 144 (27%) patients started zoledronate after a median of 12.8 months for post-baseline decreases in BMD or fractures, per the protocol definition. Baseline demographics and disease characteristics were generally balanced between patients in the delayed-zoledronate arm who initiated zoledronate treatment compared with those who did not (Table 2) , with the expected exception of the proportion of patients with a T-score ≤−1 at baseline (56.3% of patients who initiated delayed zoledronate versus 21.5% of patients who did not initiate delayed zoledronate).
efficacy assessments bone mineral density
At 60 months, the mean change in lumbar spine BMD was +4.3% in the immediate-zoledronate group and −5.4% in the delayed-zoledronate group (P < 0.0001; Figure 1 ). For total hip BMD, the mean change was +1.6% in the immediatezoledronate group and −4.2% in the delayed-zoledronate group (P < 0.0001). Thus, immediate-zoledronate therapy continued to improve lumbar spine and hip BMD in patients with early breast cancer compared with delayed zoledronate, supporting early and continued use of zoledronate during adjuvant therapy for breast cancer.
Analyses based on prior chemotherapy or baseline BMD Tscore also showed marked differences in BMD between the two treatment groups. Patients who had received prior chemotherapy (n = 567; 280 assessable at analysis) had similar BMD changes as the overall population (+3.65% in the immediate-zoledronate group versus −5.784% in the delayedzoledronate group; P < 0.0001), demonstrating that both chemotherapy and letrozole can have adverse effects on BMD in patients with early breast cancer. Furthermore, in analyses by baseline BMD, patients with T-score > −1 (n = 733) recorded a substantial (−7.1%) decrease in lumbar spine BMD in the delayed-zoledronate group (versus +3.9% with immediate zoledronate; P < 0.0001), changes in BMD that are similar in magnitude to those with ostoepaenia at baseline, and indicating that patients initiating adjuvant letrozole are at high risk for BMD loss even in the absence of osteopaenia at baseline. The mean differences in lumbar spine BMD at 60 months/ early discontinuation versus baseline were similar across menopausal groups. However, in recently postmenopausal patients, immediate zoledronate preserved, but did not improve, baseline lumbar spine BMD at 60 months/early discontinuation (−0.3% change versus baseline; P = 0.7) compared with a large decrease in lumbar spine BMD (−9.3% versus baseline; P < 0.0001; Δ = 9.0%) in the delayed-zoledronate group. In contrast, in established (naturally) postmenopausal patients, immediate zoledronate substantially improved lumbar spine BMD at 60 months/early discontinuation (+5.3% versus baseline; P < 0.0001; Δ = 9.5%) compared with a more modest decrease in lumbar spine BMD (−4.2% versus baseline; P < 0.0001) in the delayed-zoledronate group.
disease recurrence and overall survival
At 60-month follow-up, patients in the immediate-zoledronate group had a 34% relative reduction in the risk of DFS events (disease recurrence or death) versus the delayed-zoledronate group (hazard ratio [HR] = 0.66; 95% confidence interval [CI] = 0.44-0.97; unstratified log-rank P = 0.0375 [ Figure 2A] ). Patients in the immediate-zoledronate group had both fewer local and distant disease recurrences versus the delayedzoledronate group (local recurrences, 0.9% versus 2.3%, respectively; distant recurrences, 5.5% versus 7.7%, respectively; Figure 3A ). Bone was the most common site for distant recurrence in both groups, and bone metastases were more common in the delayed-zoledronate group versus the immediate-zoledronate group (4.5% versus 2.6%, respectively; Figure 3B ). Contralateral breast cancers were reported in three patients in the immediate-zoledronate group versus six in the delayed-zoledronate group. 
Annals of Oncology original articles
OS was not substantially different between groups (HR = 0.69; 95% CI = 0.42-1.14; stratified log-rank P = 0.1463). At a median follow-up of 61.6 months, Kaplan-Meier estimates of OS were 95.2% (95% CI = 92.9-96.8) in the immediatezoledronate group and 93.9% (95% CI = 91.5-95.7) in the delayed-zoledronate group (supplementary Figure S2 , available at Annals of Oncology online).
DFS and OS in exploratory analyses
Because of the ZO-FAST trial design, censored analyses may provide a more accurate portrayal of the effect of zoledronate versus no zoledronate on DFS than the Intention-to-treat population. In analyses censoring patients at the time, they initiated zoledronate in the delayed arm, immediate use of zoledronate substantially improved DFS versus patients in the delayed arm (HR = 0.62; 95% CI = 0.41-0.93; P = 0.0239; Figure  2B ). Exploratory analyses of the delayed-zoledronate arm were performed. These showed that zoledronate initiation in this group (n = 144) was associated with substantially improved DFS versus no zoledronate treatment (HR = 0.46; P = 0.0334). By chance, a larger (non-significant) proportion of patients initiating delayed zoledronate treatment was lymph node positive at diagnosis (70%) versus that proportion not initiating delayed zoledronate (55%), an imbalance that would, if anything, contribute to an underestimate of DFS benefits from delayed introduction of zoledronate. Other prognostic factors identified for DFS in the delayed-zoledronate arm included, as expected, tumour stage at study entry (HR = 2.16; original articles Annals of Oncology P = 0.0416 for ≥T2 versus T0 or T1) and age at study entry (HR = 1.95; P = 0.0236 for age ≥65 versus <65 years).
Further exploratory analyses examined the effects of baseline menopausal status on DFS and OS with immediate zoledronate (Figure 4) . Analyses per protocol defined menopausal status in the ZO-FAST trial showed trends towards improved DFS with immediate zoledronate in recently menopausal (n = 177) and truly postmenopausal (n = 888) subsets (0.05 < P < 0.1). No substantial differences in OS were observed in either group with immediate versus delayed zoledronate. Moreover, exploratory analyses based on age showed that DFS at 60 months was generally better with immediate versus delayed zoledronate, although the differences within individual age groups do not appear statistically significant (i.e. 95% CIs overlap). In exploratory analyses of women with established postmenopausal status (>5 years postmenopausal or >60 years of age at study entry; n = 670), immediate zoledronate was associated with a trend for improved DFS (HR = 0.63; P = 0.0516) and substantially improved OS (HR = 0.50; P = 0.0224) versus delayed zoledronate.
safety
The most common AEs (>10% in the overall safety population) are as previously reported and summarised in supplementary Table S1 , available at Annals of Oncology online. Fractures and atrial fibrillation were statistically similar in the immediateversus delayed-zoledronate arms, and no effects on cholesterol levels were detected. Notably, renal AEs were similar between treatment arms, with a total of three AEs in the immediatezoledronate arm and two AEs in the delayed-zoledronate arm, of which only one was grade 3/4. A total of nine potential osteonecrosis of the jaw (ONJ) events from seven patients were reported in the study. Each event was independently adjudicated by an external panel; ONJ was confirmed in three cases, deemed possible (insufficient data) in two cases, and excluded in the remaining cases.
discussion
At 60-month follow-up in the ZO-FAST study, the substantial improvements in lumbar spine BMD in patients receiving immediate versus delayed zoledronate observed at 12 ( primary end point) and 36 months [6, 20] were confirmed and shown to be durable. The mean change in lumbar spine BMD was +4.3% in the immediate-zoledronate group and −5.4% in the delayed-zoledronate group (P < 0.0001). Exploratory analyses showed that changes in BMD with zoledronate were influenced by baseline menopausal status, with newly menopausal patients maintaining BMD, and postmenopausal patients improving BMD with immediate versus delayed zoledronate. Furthermore, analyses based on prior chemotherapy or baseline BMD T-score showed substantial changes in BMD in the immediate-versus delayed-zoledronate groups. Together, these data suggest that zoledronate therapy is especially important for patients with low BMD, or patients at risk for losing BMD, who are initiating letrozole therapy.
As observed after 36-month' follow-up [20] , DFS benefits remain evident with immediate versus delayed zoledronate in the current analysis. The absolute difference in DFS between the immediate-and delayed-zoledronate groups (91.9% versus 88.3%, respectively) was 3.6% after 5 years. This translated into a 34% relative reduction in the risk of disease recurrence or death at 60 months for immediate versus delayed zoledronate, which was slightly less than the 41% risk reduction observed at 36 months [20] . The DFS results could have been influenced by the initiation of zoledronate in the delayed-zoledronate group, as well the fact that 23% of patients in the immediatezoledronate group had prematurely discontinued treatment by the 60-month assessment. Indeed, censored analyses reveal a larger DFS benefit with immediate zoledronate, and exploratory analyses also suggest a DFS benefit from initiating zoledronate treatment in the delayed arm. This observation of potential benefit from late intervention with an effective adjuvant therapy is reminiscent of the benefits seen with delayed introduction of letrozole in the MA-17 study of extended endocrine treatment with letrozole [5] and suggests that late intervention with zoledronate may be able to modify the fate of dormant tumour cells many years after diagnosis.
In analyses based on menopausal status at study entry, DFS and OS benefits with zoledronate were particularly marked in patients older than 60 years or more than 5 years postmenopausal. These observations are similar to the recent report from the AZURE trial [19] and support the hypothesis that the anticancer potential of zoledronate might be best realised in a low reproductive hormone environment (e.g. in established menopause). The substantial DFS benefit and trend towards an OS advantage with immediate versus delayed zoledronate in the ZO-FAST overall population are consistent with data from ABCSG-12 (N = 1803), a large prospective study that demonstrated improved DFS and OS outcomes with zoledronate (4 mg every 6 months for 3 years) versus no zoledronate in women receiving adjuvant endocrine therapy (ovarian suppression + anastrazole or tamoxifen) for early breast cancer [21] . Similar to the findings in our study, patients in ABCSG-12 who received zoledronate had fewer breast cancer recurrences in and outside bone. Taken together with results from the AZURE postmenopausal subset [19] , the ZO-FAST 5-year analyses support the emerging opinion that specific patient populations (e.g. women >5 years postmenopausal) may derive anticancer benefit from zoledronate.
limitations of the study
For the DFS analysis, ZO-FAST was limited in that the study population was nonhomogeneous, including patients with established or recent menopause. As a result, there may have been differing bone turnover rates (because of potentially more rapid BMD loss in recently menopausal women versus those with established menopause) and hormonal environments, potentially affecting the risk of breast cancer recurrences as well as zoledronate initiation in the delayed arm. However, baseline characteristics (except osteopaenia) were balanced in patients who did or did not initiate delayed zoledronate. Moreover, the menopausal status distribution of the study population also may make results more easily generalised to the typical patient population receiving adjuvant aromatase inhibitors for early breast cancer. Secondly, the effect of zoledronate initiation in the delayed-zoledronate group adds an additional layer of complexity to interpreting these data. Finally, immediate zoledronate did not alter DFS rates significantly in the companion trials, Z-FAST (HR = 0.79; 95% CI = 0.45-1.39, P = 0.416), and E-ZO-FAST (HR = 1.74; 95% CI = 0.83-3.67; P = 0.1397) [22, 23] . Because these trials were not designed to assess DFS as a primary end point, their small sizes and low event rates (Z-FAST, N = 600 with 37 disease recurrences; E-ZO-FAST, N = 527 with 29 disease recurrences [23] ), coupled with zoledronate initiation in the delayed arms, might have underpowered them for between-group differences in DFS compared with ZO-FAST (N = 1065 with 87 disease recurrences [104 DFS events]). Finally, letrozole was the only aromatase inhibitor included in the study, and it is not known whether these observations will translate to other hormonal therapies for postmenopausal breast cancer.
perspective
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